Video Experimental Relacionado
Updated: Jan 18, 2026
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
Enfermedad de Alzheimer: una actualización sobre la patobiología y las estrategias de tratamiento
Justin M Long1, David M Holtzman1
1Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cell
|October 1, 2019
Resumen
La enfermedad de Alzheimer (EA) implica una patobiología compleja más allá de las placas amiloides y los ovillos de tau. La investigación destaca nuevos procesos celulares, pero aún se necesitan tratamientos efectivos para la enfermedad de Alzheimer.
Área de la Ciencia:
- Neurología
- La neurociencia
- Patología
Sus antecedentes:
- La enfermedad de Alzheimer (EA) se caracteriza por placas amiloides y ovillos neurofibrilares.
- Descubrimientos recientes revelan otros procesos celulares y moleculares críticos involucrados en la patobiología de la EA.
- Los tratamientos actuales para la EA no modifican la enfermedad y los ensayos clínicos han tenido un éxito limitado.
Objetivo del estudio:
- Revisar los avances recientes en la comprensión de la patobiología de la enfermedad de Alzheimer.
- Para discutir las estrategias actuales de tratamiento de la enfermedad de Alzheimer y los ensayos clínicos.
- Identificar oportunidades para desarrollar futuras terapias modificadoras de la enfermedad de Alzheimer.
Principales métodos:
- Revisión de la literatura de recientes descubrimientos fundamentales en la patobiología de la enfermedad de Alzheimer.
- Análisis de las estrategias de tratamiento actuales y los resultados de los ensayos clínicos de fase 3.
- Exploración de investigaciones emergentes para nuevos objetivos terapéuticos.
Principales resultados:
- La patobiología de la enfermedad de Alzheimer es más compleja de lo que se entendía anteriormente, e involucra múltiples vías celulares y moleculares.
- A pesar de las extensas investigaciones, actualmente no se dispone de tratamientos definitivos para la enfermedad de Alzheimer.
- Numerosos ensayos clínicos no han demostrado beneficios significativos, lo que subraya la necesidad de nuevos enfoques.
Conclusiones:
- Una comprensión completa de la compleja patobiología de la EA es crucial para desarrollar tratamientos efectivos.
- Las futuras estrategias terapéuticas para la enfermedad de Alzheimer deben considerar una gama más amplia de mecanismos patológicos.
- La investigación continua sobre nuevos objetivos y enfoques es esencial para avanzar en el tratamiento de la EA.
Más Videos Relacionados
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.7K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.7K
Videos de Conceptos Relacionados
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:24Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
01:30Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526
03:03Amyloid Fibrils
11.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.7K